Cardiac Allograft Vasculopathy: An Update

Heart Failure Clinics

Volumn 3, Issue 1, 2007, Pages 87-95

  Sipahi, Ilke ^a   Starling, Randall C ^a  

^a Kaufman Center for Heart Failure   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GANCICLOVIR; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ANGIOCARDIOGRAPHY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INTRAVASCULAR ULTRASOUND; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PUVA; REVIEW;

CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DISEASE PROGRESSION; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROTEIN KINASES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 34249696556     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.02.007     Document Type: Review

References (62)

1. Benza R.L., and Tallaj J. Cardiac allograft vasculopathy (chronic rejection). In: Kirklin J.K., Young J.B., and McGiffin D.C. (Eds). Heart transplantation (2002), Churchill Livingstone, Philadelphia 615-665
2. Tambur A.R., Pamboukian S., Costanzo M.R., et al. Genetic polymorphism in platelet-derived growth factor and vascular endothelial growth factor are significantly associated with cardiac allograft vasculopathy. J Heart Lung Transplant 25 6 (2006) 690-698
3. Forbes R.D., Zheng S.X., Gomersall M., et al. Irreversible chronic vascular rejection occurs only after development of advanced allograft vasculopathy: a comparative study of a rat cardiac allograft model using a retransplantation protocol. Transplantation 63 5 (1997) 743-749
4. Hosenpud J.D., Everett J.P., Morris T.E., et al. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation 92 2 (1995) 205-211
5. Costanzo-Nordin M.R. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 11 3 Pt 2 (1992) S90-S103
6. Yamani M.H., Yousufuddin M., Starling R.C., et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy?. J Heart Lung Transplant 23 3 (2004) 272-276
7. Michaels P.J., Espejo M.L., Kobashigawa J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 1 (2003) 58-69
8. McGiffin D.C., Savunen T., Kirklin J.K., et al. Cardiac transplant coronary artery disease. A multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg 109 6 (1995) 1081-1088 [discussion: 8-9]
9. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17 8 (1998) 744-753
10. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 38 1 (2001) 206-213
11. Caforio A.L., Tona F., Fortina A.B., et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4 6 (2004) 962-970
12. Sharples L.D., Caine N., Mullins P., et al. Risk factor analysis for the major hazards following heart transplantation-rejection, infection, and coronary occlusive disease. Transplantation 52 2 (1991) 244-252
13. Mehra M.R., Stapleton D.D., Ventura H.O., et al. Influence of donor and recipient gender on cardiac allograft vasculopathy. An intravascular ultrasound study. Circulation 90 5 Pt 2 (1994) II78-II82
14. Erinc K., Yamani M.H., Starling R.C., et al. The influence of donor gender on allograft vasculopathy: evidence from intravascular ultrasound. Transplant Proc 36 10 (2004) 3129-3131
15. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 76 5 Pt 2 (1987) V56-V61
16. Escobar A., Ventura H.O., Stapleton D.D., et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 74 10 (1994) 1042-1046
17. Park J.W., Merz M., Braun P., et al. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 15 6 (1996) 572-579
18. Pethig K., Heublein B., Kutschka I., et al. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 19 Suppl 3 (2000) III233-III236
19. Hognestad A., Endresen K., Wergeland R., et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42 3 (2003) 477-482
20. Everett J.P., Hershberger R.E., Norman D.J., et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 11 3 Pt 2 (1992) S133-S137
21. Petrakopoulou P., Kubrich M., Pehlivanli S., et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 110 11 Suppl 1 (2004) II207-II212
22. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 2 (2004) 169-177
23. Haji S.A., Avery R.K., Yamani M.H., et al. Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy. J Heart Lung Transplant 25 3 (2006) 294-297
24. Haji S.A., Starling R.C., Avery R.K., et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 23 3 (2004) 277-283
25. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268 7 (1992) 877-881
26. Kutschka I., Pethig K., Harringer W., et al. Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy. J Heart Lung Transplant 23 11 (2004) 1260-1265
27. Miner S.E., Cole D.E., Evrovski J., et al. Hyperhomocysteinemia and transplant coronary artery disease in cardiac transplant recipients. Clin Transplant 15 4 (2001) 258-262
28. Potena L., Grigioni F., Magnani G., et al. Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study. Am J Transplant 5 9 (2005) 2258-2264
29. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 15 (2006) 1578-1588
30. Yamani M.H., Starling R.C., Cook D.J., et al. Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. Circulation 108 14 (2003) 1724-1728
31. Yamani M.H., Cook D.J., Tuzcu E.M., et al. Systemic up-regulation of angiotensin II type 1 receptor in cardiac donors with spontaneous intracerebral hemorrhage. Am J Transplant 4 7 (2004) 1097-1102
32. Yamani M.H., Cook D.J., Tuzcu E.M., et al. Systemic activation of integrin alphaVbeta3 in donors with spontaneous intracerebral hemorrhage is associated with subsequent development of vasculopathy in the heart transplant recipient. J Heart Lung Transplant 24 8 (2005) 1014-1018
33. Radovancevic B., Poindexter S., Birovljev S., et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 4 6 (1990) 309-312 [discussion: 13]
34. Hoang K., Chen Y.D., Reaven G., et al. Diabetes and dyslipidemia. A new model for transplant coronary artery disease. Circulation 97 21 (1998) 2160-2168
35. Uretsky B.F., Murali S., Reddy P.S., et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76 4 (1987) 827-834
36. Lim T.T., Liang D.H., Botas J., et al. Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study. Circulation 95 4 (1997) 855-859
37. Ramasubbu K., Schoenhagen P., Balghith M.A., et al. Repeated intravascular ultrasound imaging in cardiac transplant recipients does not accelerate transplant coronary artery disease. J Am Coll Cardiol 41 10 (2003) 1739-1743
38. Tuzcu E.M., Hobbs R.E., Rincon G., et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation 91 6 (1995) 1706-1713
39. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 98 24 (1998) 2672-2678
40. Li H., Tanaka K., Anzai H., et al. Influence of pre-existing donor atherosclerosis on the development of cardiac allograft vasculopathy and outcomes in heart transplant recipients. J Am Coll Cardiol 47 12 (2006) 2470-2476
41. Tuzcu E.M., Kapadia S.R., Sachar R., et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 45 9 (2005) 1538-1542
42. Mehra M.R., Ventura H.O., Stapleton D.D., et al. The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. J Heart Lung Transplant 14 6 Pt 2 (1995) S207-S211
43. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 10 (1995) 621-627
44. Fang J.C., Kinlay S., Beltrame J., et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 359 9312 (2002) 1108-1113
45. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 9 (2003) 847-858
46. Spes C.H., Klauss V., Mudra H., et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation 100 5 (1999) 509-515
47. Tona F., Caforio A.L., Montisci R., et al. Coronary flow velocity pattern and coronary flow reserve by contrast-enhanced transthoracic echocardiography predict long-term outcome in heart transplantation. Circulation 114 1 Suppl (2006) I49-I55
48. Young J.B. Allograft vasculopathy: diagnosing the nemesis of heart transplantation. Circulation 100 5 (1999) 458-460
49. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40 9 (2002) 1609-1614
50. Grigioni F., Carigi S., Potena L., et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc 38 5 (2006) 1507-1510
51. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 11 (2005) 1736-1740
52. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 3 (1993) 164-170
53. Mehra M.R., Ventura H.O., Smart F.W., et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 75 12 (1995) 853-854
54. Erinc K., Yamani M.H., Starling R.C., et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant 24 8 (2005) 1033-1038
55. de Lorgeril M., Boissonnat P., Mamelle N., et al. Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. Circulation 89 6 (1994) 2590-2594
56. de Lorgeril M., Dureau G., Boissonnat P., et al. Increased platelet aggregation after heart transplantation: influence of aspirin. J Heart Lung Transplant 10 4 (1991) 600-603
57. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Curr Control Trials Cardiovasc Med 1 3 (2000) 166-171
58. Simpson L., Lee E.K., Hott B.J., et al. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant 24 9 (2005) 1211-1217
59. Bader F.M., Kfoury A.G., Gilbert E.M., et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant 25 3 (2006) 298-301
60. Benza R.L., Zoghbi G.J., Tallaj J., et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 43 11 (2004) 1973-1981
61. Halle III A.A., DiSciascio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 1 (1995) 120-128
62. Musci M., Pasic M., Meyer R., et al. Coronary artery bypass grafting after orthotopic heart transplantation. Eur J Cardiothorac Surg 16 2 (1999) 163-168